TICKERNERD
Menu
LYELLYELHealthcare · Biotechnology

LYEL Stock Forecast: Lyell Immunopharma, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$15
−5.09% on the day

The 8 Wall Street analysts covering Lyell Immunopharma, Inc. hold a median 12-month price target of $42 — +181.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$380.6M
Ticker Nerd rank
65 / 100
Median analyst target
$42
Analysts covering
8
Total return, dividends reinvested
1W
+8.8%
1M
+16.7%
YTD
−52.1%
1Y
+37.0%
From 52W high
−61.8%
From 52W low
+34.5%
$11
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LYEL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lyell Immunopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Accruals
88
Revisions
64
Size
58
Quality
50
Value
44
Momentum
43
Volatility
38
Issuance
27

Growth (93): Sales and profits are climbing, and climbing faster than before.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LYEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LYEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26LYELHigh $49Median $42Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy0 Hold1 Sell
Low $12Median $42High $49

The green dot is the last close — the median target sits +181.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2026StifelInitiatesBuy$36
22 July 2026B. Riley SecuritiesInitiatesBuy$44
22 July 2026B. Riley SecuritiesInitiatesBuy—
15 June 2026CitizensReiteratesMarket Outperform$34
15 June 2026CitizensReiteratesMarket Outperform—
15 June 2026NeedhamReiteratesBuy—
15 June 2026NeedhamReiteratesBuy$44
9 June 2026HC Wainwright & Co.ReiteratesBuy—
9 June 2026HC Wainwright & Co.ReiteratesBuy$45
8 June 2026NeedhamReiteratesBuy$44
8 June 2026NeedhamReiteratesBuy—
3 June 2026HC Wainwright & Co.ReiteratesBuy—
7 May 2026NeedhamReiteratesBuy—
10 Apr 2026NeedhamInitiatesBuy—
9 Mar 2026CitizensInitiatesMarket Outperform—
9 Dec 2025HC Wainwright & Co.UpgradeBuy—
24 Nov 2025HC Wainwright & Co.MaintainsNeutral—
26 Sept 2025LUCID CAPITAL MARKETSInitiatesBuy—
24 June 2025HC Wainwright & Co.MaintainsNeutral—
16 Apr 2025HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LYEL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LYEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Lyell Immunopharma, Inc. (LYEL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
14095.0×

Cheaper than 1% of US stocks

Price / book
1.6×

Cheaper than 56% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
−50.0%

Higher than 5% of US stocks

Earnings growth (YoY)
−50.0%

Higher than 10% of US stocks

Gross margin
—
Operating margin
−1183425.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−93.3%

Higher than 14% of US stocks

Return on assets
−34.2%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LYEL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LYELLyell Immunopharma, Inc.$380.6M
65
RCKTRocket Pharmaceuticals, Inc.$379.9M
52
UPBUpstream Bio, Inc.$381.8M
31
ARCTArcturus Therapeutics Holdings, Inc.$382.1M
61
LXEOLexeo Therapeutics, Inc.$383.2M
31
ENTAEnanta Pharmaceuticals, Inc.$388.6M
87
IPSCCentury Therapeutics, Inc.$371.9M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lyell Immunopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LYEL news & analysis

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Benzinga · 6 Aug 2026positive

Benzinga reported that an analyst initiated coverage on Lyell Immunopharma, Inc. (LYEL) on a bullish note, as part of a list of top analyst initiations for Thursday. The item notes the coverage change without providing further details.

Why it matters — A new analyst initiation with a bullish stance draws attention to LYEL from the investment community and may influence how investors view the company.

FAQ

Frequently asked questions about LYEL stock

What is the LYEL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Lyell Immunopharma, Inc. have a median 12-month price target of $42, with estimates ranging from $12 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LYEL stock a buy right now?

Of the 8 analysts covering Lyell Immunopharma, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Lyell Immunopharma, Inc. 65 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LYEL?

As at 22 Aug 2026, Lyell Immunopharma, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will LYEL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +181.5% from the last close, and Ticker Nerd's factor model ranks Lyell Immunopharma, Inc. 65 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LYEL stock forecast for 2030?

No analyst covering Lyell Immunopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LYEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $49 over the next 12 months.

How has LYEL stock performed over the past year?

Lyell Immunopharma, Inc. returned +37.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lyell Immunopharma, Inc. do?

Lyell Immunopharma Inc. is a cutting-edge biotechnology company dedicated to pioneering advancements in cell therapy for cancer treatment.

What is the latest news on LYEL?

The most recent item we track (Benzinga, 6 Aug 2026): "This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday". Benzinga reported that an analyst initiated coverage on Lyell Immunopharma, Inc. (LYEL) on a bullish note, as part of a list of top analyst initiations for Thursday. The item notes the coverage change without providing further details.

Company

About Lyell Immunopharma, Inc.

Lyell Immunopharma Inc. is a cutting-edge biotechnology company dedicated to pioneering advancements in cell therapy for cancer treatment. This innovative firm focuses on developing therapeutic platforms aimed at enhancing the functionality of T-cells, a critical component of the body’s immune response against malignancies. Lyell's primary goal is to overcome the limitations of current cell therapies, which often face challenges such as ineffective tumor infiltration and exhaustion of T-cells in challenging tumor microenvironments. The company’s work has significant implications across the healthcare and oncology sectors, potentially transforming the landscape of cancer treatment by providing more effective and personalized therapeutic options. In pursuing scientific breakthroughs, Lyell Immunopharma collaborates with leading researchers and institutions, fostering an environment that encourages innovation and discovery. As a player in the rapidly growing field of immunotherapy, Lyell Immunopharma holds a crucial role in the biopharmaceutical market. The firm’s commitment to research and development underscores its potential to provide impactful medical solutions and enhance the efficacy of cell-based therapies in combating cancer, ultimately aiming to improve patient outcomes globally.

CEO Dr. Lynn Seely M.D., Ph.D. · 161 employees · United States · https://www.lyell.com